Q2/2025: Ongoing strong revenue and EPS growth, guidance for organic revenue growth raised 

 

• Group revenue¹ at €5,571 million with organic growth of 5%^1,2 driven by consistent delivery across the core businesses Fresenius Kabi and Fresenius Helios as well as ongoing execution of #FutureFresenius. 
   
• Group EBIT¹ broadly stable³ in constant currency at €654 million impacted by the headwinds from ceased energy relief payments at Helios Germany and the loss of the volume-based procurement tender for the nutrition product Ketosteril in China at Fresenius Kabi; Group EBIT margin¹ at 11.7%. 
   
• Net income^1,4 with strong 8%³ growth in constant currency to €412 million outpacing revenue growth.
   
• EPS^1,4 rose by strong 8%³ in constant currency to €0.73 demonstrating continued bottom-line delivery based on operating strength and significantly decreased interest expenses. 
   
• Net debt/EBITDA ratio at 3.1x^1,5 driven by resumed dividend payment in Q2/25.
   
• Pro rata sale of Fresenius Medical Care shares to maintain current stake in response to the announced Fresenius Medical Care share buyback program.

 

¹Before special items
²Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
³Growth rate adjusted for Argentina hyperinflation
⁴Excluding Fresenius Medical Care
⁵At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend, net debt adjusted for the valuation effect of the equity-neutral exchangeable bond
 

Michael Sen, CEO of Fresenius: “Fresenius has demonstrated a resilient and consistent performance in the first half of 2025, with another quarter of strong momentum reflected by 8% Core EPS growth. Fresenius Kabi and Fresenius Helios continue to deliver strong results despite macroeconomic challenges, thanks to our focused strategy and disciplined execution. This performance enables us to raise our guidance, increasing our full-year expectations for revenue growth to between 5% and 7%. #FutureFresenius is paying off.

Our ambitions remain unchanged: Our current strategy phase Rejuvenate will focus on organic growth through disciplined capital allocation - upgrading our core, and scaling our platforms to enhance performance further. We are committed to delivering profitable growth through targeted investments in health and digital innovation, which together will create and enhance value for our stakeholders."

 

Guidance raised for Fiscal Year 2025¹ 

Based on the consistent growth at the top-end of the 2025 guidance in H1/25, organic revenue guidance was raised:
Fresenius Group²: organic revenue growth³ now expected in the range of 5 to 7% (previous: 4 to 6%); constant currency EBIT growth⁴ in the range of 3% to 7%
Fresenius Kabi⁵: organic revenue growth³ in the mid- to high-single-digit percentage range; EBIT margin of 16.0% to 16.5% 
Fresenius Helios⁶: organic revenue growth in the mid-single-digit percentage range; EBIT margin around 10%
 

Assumptions to guidance: When Fresenius gave guidance in February, the company acknowledged the fast-moving macro-economic and geopolitical environment, resulting in a higher level of operational uncertainty. Fresenius’ guidance continues to reflect current factors and known uncertainties such as impacts from tariffs to the extend they can currently be assessed. The guidance does not take into account potential extreme scenarios that could affect the company, its peers, and the healthcare sector as a whole.
 

¹Before special items
²2024 base: €21,526 million (revenue) and €2,489 million (EBIT)
³Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
⁴Growth rate adjusted for Argentina hyperinflation
⁵2024 base: €8,414 million (revenue) and €1,319 million (EBIT)
⁶2024 base: €12,739 million (revenue) and €1,288 million (EBIT)
 

 

Fresenius Group – Business development Q2/25

In Q2/2025, the good operating performance of Fresenius Kabi and Fresenius Helios led to a 5%¹ Group organic revenue  increase to €5,571 million. 

As expected, Group EBIT before special items was broadly stable³ in constant currency, and amounted to €654 million. This is related to the headwinds from the absence of energy relief payments at Helios Germany and the Volume Based Procurement of the nutrition product Ketosteril in China at Fresenius Kabi. Despite the negative effects, Group EBIT margin was 11.7% (Q2/24: 12.2%). The Helios Performance Programme is advancing with increasing contributions expected in the second half of the year.

Earnings per share^2,4 rose by a strong 8%³ in constant currency to €0.73, driven by the operating strength and the significantly decreased interest expenses.

Following the announcement of Fresenius Medical Care AG (FME) in June 2025 to initiate a share buyback program, Fresenius intends to sell shares of FME on a pro rata basis to maintain its current stake of around 28.6% in FME. The final size and tranching of the sale of shares will be determined based on the structure of the share buyback program of FME. As previously announced, Fresenius remains a committed shareholder and will retain no less than 25 per cent plus one share of FME.

Fresenius will use the proceeds to invest in its core business in line with the #FutureFresenius strategy and Fresenius' stated capital allocation priorities, including further strengthening the balance sheet, reducing leverage, and delivering shareholder value and long-term growth.

 

¹Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
²Before special items
³Growth rate adjusted for Argentina hyperinflation
⁴Excluding Fresenius Medical Care

 
 

Operating Companies – Business development Q2/25 

Fresenius Kabi delivered a strong performance; Growth Vectors with ongoing momentum, continued Biopharma strength; licensing agreement to commercialize a proposed vedolizumab biosimilar candidate

Organic revenue growth of 6%³ mainly driven by the Growth Vectors and the good contribution from Pharma; reflecting the less pronounced positive Argentina pricing effects; revenue was broadly flat at €2,111 million due to currency effects; increased by 5%² in constant currency.

• Growth Vectors with good organic revenue³ increase of 7%: MedTech 5%, Nutrition 1%, Biopharma 33%.
   
• Nutrition revenue: €581 million, growth clearly influenced by the tender impact from the Volume Based Procurement (VBP) on Ketosteril in China (ex Ketosteril healthy organic growth in line with ambition range), good development in Latin America and Europe; in the U.S. ongoing successful roll-out of lipid emulsions.
  • Biopharma revenue: €190 million, positive development mainly driven by the Tyenne biosimilar ramp up in Europe and the U.S. as well as Idacio; denosumab biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) launched in the U.S. and approved in Europe; expansion of autoimmune biosimilars portfolio: licensing agreement with Polpharma Biologics to commercialize a proposed vedolizumab biosimilar candidate (excluding region MENA).
  • MedTech revenue: €392 million, increase driven by the expansion in Cell Therapy in the U.S., and solid growth in Europe.
  • Pharma revenue: €947 million, strong organic revenue development³ with 5% growth based on good volumes including I.V. fluids in the U.S., and Europe with favourable pricing.
     
• EBIT¹ of Fresenius Kabi with 5%² constant currency increase to €346 million, driven by the strong margin development of the Pharma, MedTech and Biopharma business and ongoing improvements in the cost base. The EBIT margin¹ was at the upper end of the guidance range at 16.4% despite transaction exchange rate effects and headwinds on the Nutrition business in China.
• EBIT¹ of the Growth Vectors increased 3%² in constant currency against the backdrop of the Ketosteril effect, and amounted to €166 million; EBIT margin¹ at 14.3%.
• EBIT¹ of Pharma increased 16%² in constant currency to €206 million. EBIT margin¹ was strong at 21.7% due to ongoing cost savings and some one-timers.

 

Fresenius Helios with solid organic revenue growth; expected softness in profitability at Helios Germany partially offset by good development at Helios Spain; Helios Performance Programme is advancing.
 

Strong 5% organic revenue growth driven by Helios Germany (6% organic growth); Helios Spain at 3% organic growth (H1/25: 5%) linked to the Easter effect, which resulted into less activity at the beginning of Q2/25 and impacted growth predominantly at Helios Spain; revenue before special items increased by 5% in constant currency to €3,370 million.
 

• Helios Germany with revenue¹ of €2,001 million; growth mainly driven by price effects, as well as good activity levels and case mix.
• Helios Spain with revenue of €1,369 million, impacted by the Easter timing and currency translation effects related to the clinics in Latin America. The clinics in Latin America showed a good operational performance.
• EBIT¹ of Fresenius Helios as expected declined -5% in constant currency to €337 million impacted by the absence of energy relief funds in Germany. This expected softness was partially compensated by the excellent profitability at Helios Spain. EBIT margin¹ of Fresenius Helios was resilient at 10.0%.
• EBIT¹ of Helios Germany decreased by -4% to €150 million against the high prior-year base which included energy relief funds; EBIT margin at 7.5% improved by 90 bps compared to Q4/24 (6.6%), the first quarter without energy relief funds.
• EBIT¹ of Helios Spain decreased by -5% in constant currency to €189 million related to a very strong prior-year base and the Easter effect; EBIT margin¹ at a strong 13.8%.
• Helios performance programme is advancing; ramp-up in H2/25 expected with more meaningful EBIT contributions, as some of the levers are process-related and will take time to deliver and realize benefits.

 

¹Before special items
²Growth rate adjusted for Argentina hyperinflation.
³Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

 

Conference call and Audio webcast 
As part of the publication of the Q2/2025 results, a conference call will be held on August 6, 2025 at 
1:30 p.m. CEST / 7:30 a.m. EDT. All investors are cordially invited to follow the conference call in a live audio webcast at https://www.fresenius.com/investors. Following the call, a replay will be available on our website.

Contact for shareholders
Investor Relations
Telephone: + 49 61 72 6 08-24 87
Telefax: + 49 61 72 6 08-24 88
E-mail: ir-fre@fresenius.com

Information on Fresenius share and ADRs

 

Note on the presentation of financial figures 
 

• If no timeframe is specified, information refers to Q2/2025.
• Consolidated results for Q2/25 as well as for Q2/24 include special items. An overview of the results for Q2/2025 - before and after special items – is available on our website.
• Growth rates in constant currency of Fresenius Kabi are adjusted. Adjustments relate to the hyperinflation in Argentina. Accordingly, constant currency growth rates of the Fresenius Group are also adjusted.
• The results of Fresenius Helios and accordingly of the Fresenius Group for Q2/24 are adjusted by the sale of the fertility services group Eugin and the divestment of the majority stake in the hospital Clínica Ricardo Palma hospital in Lima, Peru.
• Information on the performance indicators is available on our website at https://www.fresenius.com/alternative-performance-measures.
   

 

 

 

Fresenius has published the Aide Memoire ahead of its Q2 2025 financial reporting. The Aide Memoire is a summary of relevant information that Fresenius has previously communicated previously to the capital market or otherwise made publicly available . The document may prove helpful in assessing Fresenius' financial performance ahead of the publication of quarterly results.

The Q2 2025 Aide Memoire is now available on the Fresenius Investor Relations website. The results of the second quarter and first half of 2025 of Fresenius SE & Co. KGaA will be published on 6 August 2025. The Quiet Period will start on 24 July 2025.
 

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence^®(1) (denosumab-bnht) and Bomyntra^®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia^®(3) (denosumab) and Xgeva^®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence^®(1)  and Bomyntra^®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia^®(3) and Xgeva^®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence^®(1) (denosumab-bnht) and Bomyntra^®(2) (denosumab-bnht).

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia^®(3) (denosumab) and Xgeva^®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.

This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.

Conexxence^®(1)  and Bomyntra^®(2)  are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia^®(3) and Xgeva^®(4) are registered trademarks of Amgen Inc.

Read the full press release here.

Fresenius‘ Sustainability Advisory Board met at Quirónsalud to experience how digital innovation and value-based healthcare are transforming medical care

Fresenius’ Sustainability Advisory Board (SAB) convened for its second meeting this year, with a focus on how our sustainability ambitions impact patients. Spanning June 2nd and 3rd, Michael Moser, member of the Fresenius management board and responsible for sustainability management, invited the SAB to Madrid, where our external sustainability experts were joined by representatives of the Fresenius Supervisory Board and experts from Group and Quirónsalud.  

“Delivering the highest quality in our products and services – always with a clear focus on patient needs and satisfaction — is a core pillar of our sustainability strategy. It’s inspiring to see how our colleagues at Quirónsalud are embracing digitalization to enhance diagnostics and treatments while elevating the patient experience. We’re not just improving care, we’re transforming it - for the benefit of our patients,“ emphasized Michael Moser.

Firsthand insights into leading healthcare institutions  

During their visit, the participants gained hands-on insights into how our commitment to high-quality, human-centered care is brought to life. They toured two Quirónsalud hospitals, both of which rank among Spain’s leading healthcare institutions: the Jiménez Díaz Foundation University Hospital, with over 90 years of history and a legacy as a pioneer in research and surgery, offering highly specialized, multidisciplinary care; and the University Hospital Rey Juan Carlos, known for its modern infrastructure and patient-focused design, which continues to attract a growing number of patients each year.  

A highlight of the visit was a tour of the operating rooms. There, participants observed how surgical workflows are managed with exceptional precision. Processes are optimized for timing, minimized wait times, improved patient safety, and full traceability through digital health tools. “This high level of efficiency not only ensures excellent clinical outcomes but also enables the hospital to increase the number of patients who trust us year after year, ultimately improving access to care for those who need it,” said Javier Arcos, General Manager of the Fundación Jiménez Díaz.  

Another standout moment was the live demonstration of Casiopea, an integrated digital platform, and Scribe, an AI-powered tool designed to automate doctor-patient interview transcriptions. The implementation of these solutions boosts operational efficiency and enhances the quality of care and patient experience.  

The meeting also focused on Quirónsalud’s strategic approach to quality management and its experience in implementing the Value-Based Healthcare (VBHC) model. This care model is characterized by a holistic treatment approach - enabled by cross-functional collaboration and a consistent focus on treatment outcomes, supported by measurable goals and metrics, and digital tools. Quirónsalud has been implementing this model since 2020.  

Fiona Adshead, member of the SAB and current Chair of the Sustainable Healthcare Coalition, welcomed the company’s efforts: “From my perspective, Quirónsalud is on the right path putting patients at the center of care by embracing the value-based care model. Their inspirational approach of using data and technology to transform care is delivering tangible benefits for patients, optimizing health system resource use, and supporting sustainable business success.”

Anke Schmidt (55) has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who has headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities. Anke Schmidt will report directly to the CEO of Fresenius, Michael Sen.

“With Anke Schmidt we have won an internationally experienced and highly recognized communications expert for Fresenius. With her many years of experience at DAX 40 companies, she will further strengthen our positioning as a leading global healthcare company and continue to build our brand, while also driving the strategic development of the communications function. Especially in this current phase of #FutureFresenius, Rejuvenate, it is about setting new impulses to shape an innovative, relevant, and sustainably successful Fresenius,” says Michael Sen, CEO of Fresenius. “Dennis Hofmann has reorganized and strengthened the global communications function at Fresenius in recent years. Under his leadership, the communications team played a decisive role in positioning Fresenius in the initial phase of its transformation. I would like to sincerely thank him for his great work and commitment and to wish him all the best for his future endeavors.”

Before joining Fresenius, Anke Schmidt served as Global Vice President Corporate Communications & Government Relations at Beiersdorf from 2020 onwards. Prior to that, she spent 24 years in various senior roles in Communications, Government Relations, and Human Resources at BASF, both in Germany and abroad. From 2016 to 2020, she was responsible for BASF Group’s Corporate Communications & Government Relations. Anke Schmidt studied French, economics, and political science at the University of Hamburg and the Université de Nantes in France.

# # #

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com.
Visit our media center: www.fresenius.com/media-center

Fresenius announced today that the internationally experienced and highly recognized communications expert Anke Schmidt has been appointed Head of Corporate Communications at Fresenius, effective June 1, 2025. She will succeed Dennis Hofmann, who headed the global communications function at Fresenius since September 2022 and has decided to leave the company on his own request to pursue new opportunities.

Anke Schmidt joins Fresenius from Beiersdorf, where she has served as Global Vice President Corporate Communications & Government Relations since 2020. Prior to that, she held various senior roles in Communications, Government Relations, and Human Resources at BASF over a period of 24 years, both in Germany and abroad.
 

 

• Management Board and Supervisory Board approved by a large majority
• Dividend of 1.00 euro per share agreed
• Wolfgang Kirsch re-elected as Chairman of the Supervisory Board

At today’s Annual General Meeting (AGM) in Frankfurt am Main, Germany, the shareholders of Fresenius SE & Co. KGaA approved the proposals of the General Partner and the Supervisory Board with a large majority.

The actions of the General Partner and the Supervisory Board in 2024 were approved by 99.66 percent and 97.36 percent respectively. 99.98 percent voted in favor of approving the annual financial statements. 95.83 percent of the shareholders approved the compensation report for the 2024 financial year and 99.37 percent approved the dividend proposal of 1.00 euro per share. The resolutions on the remuneration for the members of the Supervisory Board and extending the authorization to hold virtual annual general meetings were also adopted with large majorities. 77.93 percent of the share capital was represented at the AGM.

Following the AGM, the newly appointed Supervisory Board of Fresenius SE & Co. KGaA re-elected Wolfgang Kirsch as its chair during its constituent meeting. Michael Diekmann and Grit Genster were also confirmed as deputy chairs and Susanne Zeidler was confirmed as chair of the Audit Committee. The shareholders previously re-elected Prof. Dr. Iris Löw-Friedrich and Dr. Christoph Zindel to the Supervisory Board in addition to Kirsch, Diekmann, and Zeidler. After 14 years in office, Prof. Dr. med. D. Michael Albrecht stepped down from the Supervisory Board. The AGM elected Prof. Dr. Ralf Kiesslich, Chairman of the Board of the University Medical Centre in Mainz, as his successor. The six employee representatives had already been elected beforehand. All Supervisory Board members were appointed for the period until the end of the 2029 AGM.

The new Supervisory Board of Fresenius SE & Co. KGaA comprises the following members:

Wolfgang Kirsch (Chairman)
Michael Diekmann (Deputy Chair)
Grit Genster (Deputy Chair)
Bernd Behlert
Tania Lara Campaña
Carsten Georg
Prof. Dr. Ralf Kiesslich
Prof. Dr. Iris Löw-Friedrich
Holger Michel
Oscar Romero de Paco
Susanne Zeidler
Dr. Christoph Zindel

* * *

About Fresenius

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com
Follow us on social media: www.fresenius.com/socialmedia

• The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger company.
• With the next phase, Rejuvenate, the focus in the years ahead will be on strengthening the core businesses, scaling platforms, and elevating performance.
• Dividend of 1.00 euro per share proposed.

Thanks to the successful ongoing implementation of its #FutureFresenius strategy, Fresenius considers itself well-positioned to continue to deliver profitable growth and create long-term value. “With #FutureFresenius, the company has a coherent strategy that it will continue to implement consistently and successfully in the interests of all stakeholders. The Supervisory Board firmly believes that Fresenius fulfils all the requirements needed to achieve its ambitious goals. We support the course that the Management Board is pursuing. On behalf of the Supervisory Board, I thank the Management Board and all employees for their outstanding work,” said Wolfgang Kirsch, Chairman of the Supervisory Board, at this year’s Annual General Meeting (AGM) in Frankfurt am Main today.

“The successful implementation of #FutureFresenius means Fresenius is now simpler, more focused, stronger, and more resilient. We are now in a better position to anticipate change more quickly and, if necessary, respond more effectively,” said Michael Sen, CEO of Fresenius. “Fresenius is essential to healthcare systems around the world – through our hospitals and our products, without which patient care would not be possible.” Furthermore, the company’s “Local for Local” strategy, focused on local value creation, manufacturing, and jobs, also strengthens its resilience.

Fresenius began the year from a position of strength and launched the next phase of its #FutureFresenius strategy, Rejuvenate. Reducing the shares in Fresenius Medical Care in March this year was the first milestone. Fresenius used the proceeds to strengthen its balance sheet and further fuel innovation. Rejuvenate is about advancing and strengthening its core businesses. In addition, the company will scale up its three platforms – (Bio)Pharma, MedTech, and Care Provision – to unlock new long-term growth opportunities and achieve higher earnings.

In the 2024 financial year, Fresenius once again increased the pace of growth in revenue and earnings. “Last year, we not only kept our promises but even exceeded our expectations and raised our guidance twice,” said Sen. The company achieved this through its efforts, to which all operating businesses contributed. Productivity also increased, and the self-imposed target corridor for the leverage ratio was achieved for the first time in seven years. By 2024, Fresenius had reduced its net debt by 2 billion euros and achieved an operating cash flow of 2.4 billion euros. A dividend of 1.00 euro per share was proposed for the past financial year during the Annual General Meeting.

Fresenius also considers itself on track for 2025. “Our mission to save and improve human lives continues to drive us forward in the new financial year. With the next phase of #FutureFresenius, we want to continue our success story in 2025,” said Sen, referring to the strong start to the year. In early May, Fresenius confirmed its guidance for the full year 2025 following excellent growth in revenue and earnings during the first quarter.

The AGM will be held in person, with several hundred shareholders attending this year’s event at Messe Frankfurt.

* * *
The letter by Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, and the speech by Michael Sen, Chief Executive Officer of Fresenius, can be downloaded here: Annual General Meeting | FSE

About Fresenius

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered n Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 176,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com
Follow us on social media: www.fresenius.com/socialmedia